From lipid detection to biological meaning: raising standards for oxylipin signaling.

Lingshuang Wu, John T Shuster, Judith A Simcox

Abstract read

In one paragraph

Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lingshuang WuDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA; Howard Hughes Medical Institute, University of Wisconsin-Madison, Madison, WI, USA.

John T ShusterDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA; Cell Molecular Biology Graduate Program, University of Wisconsin-Madison, Madison, WI, USA; Medical Scientist Training Program, University of Wisconsin-Madison, Madison, WI, USA.

Judith A SimcoxDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA; Howard Hughes Medical Institute, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: jsimcox@wisc.edu.

Funding

Integrated Training For Physician-ScientistsT32GM140935 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anna Huttenlocher, Jeniel E Nett · 2021 to 2026

$6.5M

Discovery and characterization of a novel acylcarnitine transporter in brown adipocytesR01DK133479 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI Judith Anne Simcox · 2022 to 2026

$1.5M

Defining the roles of ACAD10/11 in hydroxy lipid catabolism and metabolic diseaseR01DK137976 · NIDDK · WASHINGTON UNIVERSITY · PI David J Pagliarini · 2024 to 2026

$1.2M

Dietary ether lipid salvage by ACAD10R01HL181065 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Judith Anne Simcox, Vincent Scott Tagliabracci · 2026 to 2026

$662k

NHLBI NIH HHS R01 HL181065NIDDK NIH HHS R01 DK133479NIDDK NIH HHS R01 DK137976NIGMS NIH HHS T32 GM140935

6 · The paper itself

Abstract

The field of oxylipin research has outpaced the development of standards and guidelines. As these signaling lipids gain attention in inflammation, metabolism, and tissue repair, the field must confront a central challenge: many proposed pro-resolving mediators are difficult to measure and interpret. A recent publication by Schebb and colleagues calls for stronger evidence, from analytical detection to endogenous function.

Identifiers

PMID42727852

DOI10.1016/j.jlr.2026.101145

PMCPMC13682458

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.